Home » Stocks » MYOS

MYOS RENS Technology Inc. (MYOS)

Nov 18, 2020 - Stock symbol was changed to MDVL
Stock Price: $1.01 USD 0.00 (0.00%)
Updated Nov 17, 2020 4:00 PM EST

Stock Price Chart

Key Info

Market Cap 12.31M
Revenue (ttm) 1.48M
Net Income (ttm) -3.64M
Shares Out 12.19M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 17, 2020
Last Price $1.01
Previous Close $1.01
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.05
Day's Range 1.01 - 1.09
Day's Volume 218,840
52-Week Range 0.74 - 3.85

More Stats

Market Cap 12.31M
Enterprise Value 12.65M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.19M
Float 6.52M
EPS (basic) -0.34
EPS (diluted) -0.35
FCF / Share -0.23
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10,597
Short Ratio 0.09
Short % of Float 0.16%
Beta 1.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.30
PB Ratio 6.75
Revenue 1.48M
Operating Income -3.60M
Net Income -3.64M
Free Cash Flow -2.67M
Net Cash -337,000
Net Cash / Share -0.03
Gross Margin 42.82%
Operating Margin -242.95%
Profit Margin -245.40%
FCF Margin -180.31%
ROA -65.71%
ROE -165.90%
ROIC -179.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $1.01
Target: 3.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth186.67%-31.56%60.86%105.66%-95.24%0.75%263.92%816.54%--
Gross Profit0.640.110.220.01-0.621.921.800.050.05-
Operating Income-4.22-4.33-4.07-4.31-5.06-5.21-4.27-3.04-4.60-0.03
Net Income-4.26-3.22-4.06-4.34-5.08-4.46-4.26-3.91-5.60-0.02
Shares Outstanding8.807.145.884.813.242.852.211.841.230.98
Earnings Per Share-0.46-0.45-0.69-0.90-1.64-1.56-1.93-2.13-4.50-
Operating Cash Flow-2.37-3.25-3.78-3.67-2.25-5.09-3.15-2.35-2.16-0.04
Capital Expenditures----0.38-0.03-0.02-0.37-0.01-0.45-
Free Cash Flow-2.37-3.25-3.79-4.05-2.28-5.11-3.53-2.35-2.61-0.04
Cash & Equivalents0.060.020.921.870.881.570.453.980.06-
Total Debt1.351.02--0.68---0.900.01
Net Cash / Debt-1.29-1.000.921.870.201.570.453.98-0.84-0.01
Book Value1.182.824.365.323.516.743.346.200.47-0.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MYOS RENS Technology Inc.
Country United States
Employees 15
CEO Joseph Manello

Stock Information

Ticker Symbol MYOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: MYOS


MYOS RENS Technology focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform. It has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery of compounds and products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.